In vitro and in vivo characterization of opioid activities of endomorphins analogs with novel constrained C-terminus: Evidence for the important role of proper spatial disposition of the third aromatic ring

Peptides

Volumn 28, Issue 4, 2007, Pages 859-870

  Yu, Ye ^a   Shao, Xuan ^a,c   Wang, Chang Lin ^a   Liu, Hong Mei ^a   Cui, Yun ^a   Fan, Ying Zhe ^a   Liu, Jing ^a,d   Wang, Rui ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b LANZHOU INSTITUTE OF CHEMICAL PHYSICS   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Conformationally constrained analogs; Endomorphins; Opioid activities; Spatial orientation; Third aromatic ring

Indexed keywords

ENDOMORPHIN 1; ENDOMORPHIN 2; ENDORPHIN DERIVATIVE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTERIAL PRESSURE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COLON MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; GUINEA PIG; HEART RATE; IC 50; ILEUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SPATIAL ORIENTATION; VAS DEFERENS;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDORPHINS; GASTROINTESTINAL MOTILITY; GUINEA PIGS; HEART RATE; ILEUM; MALE; MICE; MOLECULAR STRUCTURE; PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

CAVIA;

EID: 33847345565     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.01.002     Document Type: Article

References (38)

1. Akiyama K., Gee K.W., Mosberg H.I., Hruby V.J., and Yamamura H.I. Characterization of [3H][2-d-penicillamine, 5-d-penicillamine]-enkephalin binding to delta opiate receptors in the rat brain and neuroblastoma-glioma hybrid cell line (NG 108-15). Proc Natl Acad Sci USA 82 (1985) 2543-2547
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
3. Cardillo G., Gentilucci L., Melchiorre P., and Spampinato S. Synthesis and binding activity of endomorphin-1 analogues containing beta-amino acids. Bioorg Med Chem Lett 10 (2000) 2755-2758
4. Cardillo G., Gentilucci L., Qasem A.R., Sgarzi F., and Spampinato S. Endomorphin-1 analogues containing beta-proline are mu-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance. J Med Chem 45 (2002) 2571-2578
5. Champion H.C., Bivalacqua T.J., Lambert D.G., McWilliams S.M., Zadina J.E., Kastin A.J., et al. Endomorphin 1 and 2, the endogenous mu-opioid agonists, produce biphasic changes in systemic arterial pressure in the cat. Life Sci 63 (1998) PL131-PL136
6. Champion H.C., Zadina J.E., Kastin A.J., Hackler L., Ge L.J., and Kadowitz P.J. Endomorphin 1 and 2, endogenous ligands for the mu-opioid receptor, decrease cardiac output, and total peripheral resistance in the rat. Peptides 18 (1997) 1393-1397
7. Champion H.C., Zadina J.E., Kastin A.J., and Kadowitz P.J. Endomorphin 1 and 2 have vasodepressor activity in the anesthetized mouse. Peptides 19 (1998) 925-929
8. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., and Trottier J.F. Role of endogenous opioid system in the regulation of the stress response. Prog Neuro-Psychopharmacol Biol Psychiatry 25 (2001) 729-741
9. Eddy N.B., and Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 107 (1953) 385-393
10. Fang Q., Guo J., Chang M., Chen L.X., Chen Q., and Wang R. Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon. Peptides 26 (2005) 791-797
11. Fiori S., Renner C., Cramer J., Pegoraro S., and Moroder L. Preferred conformation of endomorphin-1 in aqueous and membrane-mimetic environments. J Mol Biol 291 (1999) 163-175
12. Fischer A., and Undem B.J. Naloxone blocks endomorphin-1 but not endomorphin-2 induced inhibition of tachykinergic contractions of guinea-pig isolated bronchus. Br J Pharmacol 127 (1999) 605-608
13. Fujita Y., Tsuda Y., Li T., Motoyama T., Takahashi M., Shimizu Y., et al. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties. J Med Chem 47 (2004) 3591-3599
14. Gentilucci L., and Tolomelli A. Recent advances in the investigation of the bioactive conformation of peptides active at the micro-opioid receptor. conformational analysis of endomorphins. Curr Top Med Chem 4 (2004) 105-121
15. Haley T.J., and McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12 (1957) 12-15
16. Hruby V.J., and Agnes R.S. Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. Biopolymers 51 (1999) 391-410
17. Hughes J., Kosterlitz H.W., and Leslie F.M. Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br J Pharmacol 53 (1975) 371-381
18. Janecka A., Fichna J., Kruszynski R., Sasaki Y., Ambo A., Costentin J., et al. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. Biochem Pharmacol 71 (2005) 188-195
19. Lengyel I., Orosz G., Biyashev D., Kocsis L., Al-Khrasani M., Ronai A., et al. Side chain modifications change the binding and agonist properties of endomorphin 2. Biochem Biophys Res Commun 290 (2002) 153-161
20. Li T., Fujita Y., Tsuda Y., Miyazaki A., Ambo A., Sasaki Y., et al. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J Med Chem 48 (2005) 586-592
21. Liu J., Yu Y., Fan Y.Z., Chang H., Liu H.M., Cui Y., et al. Cardiovascular effects of endomorphins in alloxan-induced diabetic rats. Peptides 26 (2005) 607-614
22. McLay R.N., Pan W., and Kastin A.J. Effects of peptides on animal and human behavior: a review of studies published in the first twenty years of the journal Peptides. Peptides 22 (2001) 2181-2255
23. Okada Y., Fukumizu A., Takahashi M., Shimizu Y., Tsuda Y., Yokoi T., et al. Synthesis of stereoisomeric analogues of endomorphin-2, H-Tyr-Pro-Phe-Phe-NH(2), and examination of their opioid receptor binding activities and solution conformation. Biochem Biophys Res Commun 276 (2000) 7-11
24. Patel H.J., Venkatesan P., Halfpenny J., Yacoub M.H., Fox A., Barnes P.J., et al. Modulation of acetylcholine release from parasympathetic nerves innervating guinea-pig and human trachea by endomorphin-1 and -2. Eur J Pharmacol 374 (1999) 21-24
25. Paterlini M.G., Avitabile F., Ostrowski B.G., Ferguson D.M., and Portoghese P.S. Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1. Biophys J 78 (2000) 590-599
26. Przewlocki R., Labuz D., Mika J., Przewlocka B., Tomboly C., and Toth G. Pain inhibition by endomorphins. Ann NY Acad Sci 897 (1999) 154-164
27. Rang H.P. Stimulant actions of volatile anaesthetics on smooth muscle. Br J Pharmacol chemother 22 (1964) 356-365
28. Sakurada S., Hayashi T., and Yuhki M. Differential antinociceptive effects induced by intrathecally-administered endomorphin-1 and endomorphin-2 in mice. Jpn J Pharmacol 89 (2002) 221-223
29. Sasaki Y., Sasaki A., Niizuma H., Goto H., and Ambo A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high mu-opioid receptor affinity and selectivity. Bioorg Med Chem 11 (2003) 675-678
30. Schwyzer R. ACTH: a short introductory review. Ann NY Acad Sci 297 (1977) 3-26
31. Stone L.S., Fairbanks C.A., Laughlin T.M., Nguyen H.O., Bushy T.M., Wessendorf M.W., et al. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8 (1997) 3131-3135
32. Storr M., Hahn A., Gaffal E., Saur D., and Allescher H.D. Effects of endomorphin-1 and -2 on mu-opioid receptors in myenteric neurons and in the peristaltic reflex in rat small intestine. Clin Exp Pharmacol Physiol 29 (2002) 428-434
33. Tomboly C., Kover K.E., Peter A., Tourwe D., Biyashev D., Benyhe S., et al. Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem 47 (2004) 735-743
34. Tseng L.F., Narita M., Suganuma C., Mizoguchi H., Ohsawa M., Nagase H., et al. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292 (2000) 576-583
35. Yokotani K., and Osumi Y. Involvement of mu-receptor in endogenous opioid peptide-mediated inhibition of acetylcholine release from the rat stomach. Jpn J Pharmacol 78 (1998) 93-95
36. Yu Y., Cui Y., Wang X., Fan Y.Z., Liu J., Yan X., et al. Endomorphin1 and endomorphin2, endogenous potent inhibitors of electrical field stimulation (EFS)-induced cholinergic contractions of rat isolated bronchus. Peptides 27 (2006) 1846-1851
37. Yu Y., Wang C.L., Cui Y., Fan Y.Z., Liu J., Shao X., et al. C-terminal amide to alcohol conversion changes the cardiovascular effects of endomorphins in anesthetized rats. Peptides 27 (2006) 136-143
38. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502